BusinessMelinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 CountriesBy Nasdaq OMXMar 2, 2017, 1:01 PM UTC
BusinessMelinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 CountriesBy Nasdaq OMXMar 2, 2017, 1:01 PM UTC
BusinessCempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXFeb 28, 2017, 11:45 AM UTC
BusinessCempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to PresidentBy Nasdaq OMXDec 12, 2016, 2:01 PM UTC
BusinessFDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial PneumoniaBy Nasdaq OMXNov 5, 2016, 2:40 AM UTC
BusinessCempra Stock Trading Halted Today; FDA Advisory Committee to Discuss SolithromycinBy Nasdaq OMXNov 4, 2016, 11:05 AM UTC
BusinessCempra to Present at the Needham and Company 15th Annual Healthcare ConferenceBy Nasdaq OMXApr 6, 2016, 11:30 AM UTC
BusinessCempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric PatientsBy Nasdaq OMXMar 7, 2016, 12:00 PM UTC
